At what enterprise value was NEMERA acquired in 2018?

During the acquisition of NEMERA by ASTORG in 2018, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR.

What was the EV/EBITDA of NEMERA when it was acquired by ASTORG?

The estimated EV/EBITDA multiple for NEMERA is in the range of 15x - 25x.

When was NEMERA acquired by ASTORG?

NEMERA was acquired by ASTORG in 2018.

What was the revenue of NEMERA at the time of the deal?

The revenue of NEMERA at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of NEMERA during the acquisition?

NEMERA's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the NEMERA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEMERA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.astorg.com/news/montagu-and-astorg-enter-into-an-exclusive-agreement-to-form-a-partnership-on-nemera

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaNEMERA

10/2018

NEMERA acquired by ASTORG

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 1b - 4b EUR

Context

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction. The transaction is also expected to provide a strong return on investment for Astorg Partners, given Nemera's solid financial performance and growth prospects. The deal process was highly competitive, with several strategic and financial buyers participating in the auction, and Astorg Partners' offer was distinguished by its attractive financial terms and compelling growth strategy.

It is worth noting that the fund Montagu Private Equity took control of Nemera through an LBO in 2014.

NEMERA, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with NEMERA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2025	LGT CAPITAL PARTNERS	NEMERA	FRANCE	Medical Consumables
02/2014	MONTAGU PRIVATE EQUITY	NEMERA	FRANCE	Medical Consumables

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEMERA by ASTORG are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: nemera

Acquirer: astorg